Vincent Carlesi, MD
Interventional Pain Medicine · Danbury, CTNPI 1699726554
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,668 of the $7,538 with a category attached, or 75.2%. It is spread thinly across 40 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,488 and has fallen 97.1% since, to $103 in 2025.
Across 294 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Biodelivery Sciences International, Inc.$823
- Boston Scientific$744
- Collegium Pharmaceutical, Inc.$606
- AbbVie$561
- Scilex Pharmaceuticals Inc.$428
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$75010%
- Travel & lodging$1,02214%
- Food & beverage$5,66875%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$1,068
- BELBUCA$750
- iFuse Implant$383
- VOQUEZNA$124
- SPECTRA WAVEWRITER$123
- RESTORE$110
- GENERAL PAIN MANAGEMENT$109
- Senza Spinal Cord Stimulation System$103
How this compares
Too few interventional pain medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 163 | $161,196 |
| Oxycodone Hcl | 1,198 | $40,042 |
| ZtlidoLidocaine | 12 | $18,404 |
| Xtampza ErOxycodone Myristate | 30 | $16,385 |
| MovantikNaloxegol Oxalate | 33 | $14,177 |
| Hydromorphone ErHydromorphone Hcl | 20 | $11,562 |
| Fentanyl | 88 | $10,974 |
| Lidocaine | 93 | $8,759 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 297 | $8,351 |
| Morphine Sulfate ErMorphine Sulfate | 206 | $7,463 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 187 | $5,817 |
| Gabapentin | 329 | $5,711 |
| Hydromorphone Hcl | 148 | $5,546 |
| Buprenorphine | 33 | $5,174 |
| Methadone Hcl | 131 | $4,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Ztlido | $428 | $18,40412 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $606 | $16,38530 claims |
| Redhill Biopharma Inc.Movantik | $24 | $14,17733 claims |
| PfizerLyrica | $70 | $1,44011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain medicine providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other interventional pain medicine in Danbury
- Sokpoleak SoDanbury$353
- Richard LucarelliVernon$71K
- Mohan VodapallyHamden$26K
- Mark ThimineurDerby$17K
- Robert BoolbolFarmington$15K
- Shyam DesaiFairfield$14K
- Michael GrilleHartford$10K
- Jonathan KostWest Hartford$10K
- Pardeep SoodTrumbull$8K
- Dwight LighamNew Haven$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.